UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 354

Sortiert nach

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Cellular signalling, 2014-09, Vol.26 (9), p.2016-2029

2014

Volltextzugriff (PDF)

Small molecule allosteric modulators of phosphodiesterase 4

Handbook of experimental pharmacology, 2011 (204), p.167

2011

Volltextzugriff (PDF)

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial

Journal of the American Academy of Dermatology, 2022-03, Vol.86 (3), p.607-614

2022

Volltextzugriff (PDF)

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Journal of molecular structure, 2024-01, Vol.1295, p.136719, Article 136719

2024

Volltextzugriff (PDF)

Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation

Bioorganic & medicinal chemistry letters, 2019-07, Vol.29 (13), p.1654-1659

2019

Volltextzugriff (PDF)

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Frontiers in immunology, 2022-01, Vol.12, p.797390-797390

2022

Volltextzugriff (PDF)

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

Nephrology (Carlton, Vic.), 2024-03, Vol.29 (3), p.117-125

2024

Volltextzugriff (PDF)

The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s)

Biochemical journal, 2014-05, Vol.459 (3), p.539-550

2014

Volltextzugriff (PDF)

UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy

Cellular signalling, 2015-05, Vol.27 (5), p.908-922

2015

Volltextzugriff (PDF)

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

Biochemical journal, 2007-05, Vol.404 (1), p.71-80

2007

Volltextzugriff (PDF)

Phosphodiesterase 4 Inhibition Impairs Cocaine-Induced Inhibitory Synaptic Plasticity and Conditioned Place Preference

Neuropsychopharmacology (New York, N.Y.), 2012-10, Vol.37 (11), p.2377-2387

2012

Volltextzugriff (PDF)

Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus

Neuropsychopharmacology (New York, N.Y.), 2004-08, Vol.29 (8), p.1432-1439

2004

Volltextzugriff (PDF)

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK

Biochemical journal, 2010-05, Vol.428 (1), p.55-65

2010

Volltextzugriff (PDF)

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

Bioorganic & medicinal chemistry, 2011-11, Vol.19 (21), p.6356-6374

2011

Volltextzugriff (PDF)

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2016-08, Vol.16, p.S67-S73

2016

Volltextzugriff (PDF)

The cardioprotective role of small heat-shock protein 20

Biochemical Society transactions, 2014-04, Vol.42 (2), p.270

2014

Volltextzugriff (PDF)

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity

International immunopharmacology, 2011-06, Vol.11 (6), p.732-739

2011

Volltextzugriff (PDF)

PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects

Biochemical Society transactions, 2012-02, Vol.40 (1), p.210

2012

Volltextzugriff (PDF)

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

International immunopharmacology, 2012, Vol.12 (1), p.50-58

2012

Volltextzugriff (PDF)

Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Medicinal chemistry research, 2012-11, Vol.21 (11), p.3327-3335

2012

Volltextzugriff (PDF)

Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans

Biochemical pharmacology, 2004-12, Vol.68 (11), p.2229-2236

2004

Volltextzugriff (PDF)

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E 2

Biochemical pharmacology, 2003-09, Vol.66 (5), p.801-807

2003

Volltextzugriff (PDF)

Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity

Toxicologic pathology, 2006-01, Vol.34 (1), p.39-51

2006

Volltextzugriff (PDF)

Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction

Cellular and molecular life sciences : CMLS, 2006-08, Vol.63 (15), p.1725-1735

2006

Volltextzugriff (PDF)

Novel bronchodilators in the treatment of asthma and COPD

Expert opinion on therapeutic patents, 2002-01, Vol.12 (1), p.53-63

2002

Volltextzugriff (PDF)

1 – 25 von 354

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(318)

Publikationsform

Artikel
(350)
Buchkapitel
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(349)
Humans
(219)
Animals
(211)
Pharmacology & Pharmacy
(196)
Pde4
(175)
Cyclic Nucleotide Phosphodiesterases, Type 4 - Metabolism
(122)
Male
(108)
Cyclic Nucleotide Phosphodiesterases, Type 4
(102)
Phosphodiesterase 4 Inhibitors - Pharmacology
(98)
Rats
(95)
Chemistry, Medicinal
(92)
Biological And Medical Sciences
(89)
Medical Sciences
(80)
Chemistry
(77)
Physical Sciences
(77)
Phosphodiesterase Inhibitors - Pharmacology
(76)
Phosphodiesterase
(74)
Pharmacology. Drug Treatments
(72)
Mice
(70)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity

Small molecule allosteric modulators of phosphodiesterase 4

Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial

New quinoline-based PDE4 inhibitors through GSK-256066 fragment-based elaboration

Facile synthesis of carbon-11-labeled sEH/PDE4 dual inhibitors as new potential PET agents for imaging of sEH/PDE4 enzymes in neuroinflammation

The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs

Urinary liver‐type fatty acid binding protein is a biomarker reflecting renal damage and the ameliorative effect of drugs at an early stage of histone‐induced acute kidney injury

The upstream conserved regions (UCRs) mediate homo- and hetero-oligomerization of type 4 cyclic nucleotide phosphodiesterases (PDE4s)

UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy

Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays

Phosphodiesterase 4 Inhibition Impairs Cocaine-Induced Inhibitory Synaptic Plasticity and Conditioned Place Preference

Inhibition of the Phosphodiesterase 4 (PDE4) Enzyme Reverses Memory Deficits Produced by Infusion of the MEK Inhibitor U0126 into the CA1 Subregion of the Rat Hippocampus

Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia

The cardioprotective role of small heat-shock protein 20

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity

PKA phosphorylation of the small heat-shock protein Hsp20 enhances its cardioprotective effects

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor

Design, synthesis and in vitro PDE4 inhibition activity of certain quinazolinone derivatives for treatment of asthma

Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans

Inhibition of osteoclastogenesis by a phosphodiesterase 4 inhibitor XT-611 through synergistic action with endogenous prostaglandin E 2

Characterization of the Inflammatory Response to a Highly Selective PDE4 Inhibitor in the Rat and the Identification of Biomarkers that Correlate with Toxicity

Rubinstein-Taybi syndrome: molecular findings and therapeutic approaches to improve cognitive dysfunction

Novel bronchodilators in the treatment of asthma and COPD

Aktive Filter

Suchergebnisse filtern